No serious side effects or abnormal laboratory findings were observed for either mosapride or teprenone. Therefore, we believe that the 5-HT 4 agonist, mosapride, can be a first-line drug to treat FD.

and one or more days during the successive 3 days immediately prior to the symptom assessment were allocated to the pharmacotherapy with either mosapride or teprenone. A complete blood count ...